How groundbreaking new brain atlases capture development in motion

Groundbreaking brain atlases reveal dynamic neuron and glia development across species, transforming static maps into a ...
Pharmabiz

US FDA approves Novartis’ Itvisma, the only gene replacement therapy for children two years and older, teens, and adults with SMA

US FDA approves Novartis’ Itvisma, the only gene replacement therapy for children two years and older, teens, and adults with SMA: Basel Wednesday, November 26, 2025, 09:00 Hrs ...

FDA Greenlights Novartis' Gene Replacement Treatment for SMA

Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA ...
MedPage Today

FDA Gives Broad Approval to Gene Therapy for Rare Neurologic Disease

The FDA approved the intrathecal gene therapy onasemnogene abeparvovec (Itvisma) to treat spinal muscular atrophy (SMA) in ...
Medscape

FDA OKs New Formulation of SMA Gene Therapy Itvisma

Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated ...
BioSpace

Novartis Expands Spinal Muscular Atrophy Gene Therapy Market With FDA’s Itvisma Greenlight

The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access ...
The American Journal of Managed Care

FDA Approves Gene Therapy Onasemnogene Abeparvovec for Broader SMA Population

Onasemnogene abeparvovec-brve is the first gene replacement therapy approved for SMA patients aged 2 years and older, expanding access beyond infants. Phase 3 trials demonstrated significant motor ...
eLife

Ubiquitous predictive processing in the spectral domain of sensory cortex

The authors analyzed spectral properties of neural activity recorded using laminar probes while mice engaged in a global/local visual oddball paradigm. They found solid evidence for an increase in ...

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function ...
Pharmaceutical Technology

Novartis secures approval from FDA for Itvisma to treat SMA

Novartis has received approval from the US Food and Drug Administration (FDA) for the Itvisma gene replacement therapy to ...

FDA approves Novartis’ Itvisma, first gene therapy for SMA patients 2 and older

Novartis ( NVS) on Monday said that the U.S. FDA has approved Itvisma for the treatment of children two years and older, ...
TipRanks on MSN

Novartis receives FDA approval for Itvisma

Novartis (NVS) “announced that the US Food and Drug Administration has approved Itvisma, onasemnogene abeparvovec-brve, for the treatment of ...